Endocrinology
- DISEASE INDICATIONS: Primary hyperoxaluria type 1 (PH1)
- MANUFACTURER: Alnylam Pharmaceuticals
- USAGE: Subcutaneous
- MEDICINE APPROVED BY:
- European Medical Agency (EMA)
- Food and Drug Administration (FDA)
Oxlumo (lumasiran) is a prescription medication used to treat primary hyperoxaluria type 1 (PH1), a rare genetic disorder that causes the body to produce too much oxalate.
$65,821.80
Select optionsThis product has multiple variants. The options may be chosen on the product page